Nephrolithiasis against type 2 diabetes mellitus: on the effect of hypoglycemic therapy on lithogenesis

• Published in: Terapevtic̆eskii arhiv Vol. 90; no. 10; pp. 60 - 64
• Main Authors: Yarovoy, S K, Kareva, E N, Djalilov, O V
• Format: Journal Article
• Language: English
• Published: 01.01.2018
• ISSN: 0040-3660
• DOI: 10.26442/terarkh2018901060-64

AIMTo study the effects of oral hypoglycemic agents that can affect the probability of recurrence of nephrolithiasis.MATERIALS AND METHODSThe article is based on the results of examination and treatment of 315 patients suffering from recurrent nephroli-thiasis and medically compensated type 2 diabetes mellitus treated at the N.A. Lopatkin Institute of Urology and Interventional Radio-logy - the branch of the SMRC of Radiology, Ministry of Health of Russia and D.D. Pletnev City Hospital Moscow Healthcare -Department in 2012-2017. The patients were divided into three groups according to the applied tool antidiabetic: metformin, glibenclamide, canagliflozin. The control group consisted of patients receiving insulin therapy.RESULTSThe propensity of Metformin to reduce the pH of urine, which has a negative impact in the conditions of urate nephrolithiasis, which is most common in the population of patients with type 2 diabetes mellitus. Glibenclamide, on the contrary, somewhat latches urine. But changes in the reaction of urine under the influence of the drug do not go beyond normal values and are not clinically significant. Canagliflozin increases diuresis due to medication induced glycosuria and stimulates renal excretion of uric acid and its salts. However canagliflozin does not cause significant shifts in the pH of urine that may somewhat negates the increased risk of recurrence of urate stone formation in the background of the uricosuric effect of the drug.CONCLUSIONDrug therapy of type 2 diabetes mellitus significantly affects the properties of urine from patients with nephrolithiasis.